The Weekly Roundup: January 2-6


ICYMI, this week we had stories about what to look forward to in 2023, psoriasis challenges, NDA submissions for berdazimer gel, and more.

What to Look Forward to in 2023

The Dermatology Times® Editorial Advisory Board members share what they hope to see in 2023.

The Latest Buzz on Psoriasis

More drugs and treatment options continue to be explored, and in 2022, there were some exciting advancements in these areas for dermatologists treating psoriasis.

The Mainstream Patient: January 3, 2023

This week's edition of the Mainstream Patient features stories about dry shampoos that don't contain benzene, the best ferulic acid serums, Hijabi hair care, and more.

The Challenges Of Winter And Psoriasis Flares

Patients with psoriasis seem to suffer more in the wintertime when flare-ups are much more common.

Treatment and Diagnosis of Merkel Cell Disease

Although Merkel cell carcinoma can develop undetected or at a metastasized site, it usually first appears as a painless lump or nodule on an area of the skin that has been exposed to the sun.

Harnessing the Immune System to Fight Basal Cell Carcinoma: What are the Risks?

In basal cell carcinoma, the most common type of skin cancer accounting for 80% of all non-melanoma skin cancers, one of the leading options for cases that fall into this category is targeted treatment with Hedgehog pathway inhibitors.

Telehealth in 2023: What Physicians Need to Know

Answers to some common questions about providing telehealth services in 2023.

The Immune Profile of Merkel Cell Carcinoma

New clues about the immune system response to MCC may be able to help guide future treatment strategies.

Pointers with Portela: Telehealth

In this week’s Pointers with Dr Portela, the 208SkinDoc discusses if telehealth is here to stay in dermatology.

Opioid Use in Psoriatic Arthritis Is Associated With Higher Health Care Costs, Utilization

New pathways of care are needed to improve health care spending.

Wound Care Market Skyrockets, but Still Lacks Standardization

New products focus on multimodal healing with absorption, antibacterial, and regenerative properties.

I Used a New Dermal Filler: How Can This Get Me Arrested for Battery?

This month's Legal Eagle column reviews how a patient tried to sue for battery due to excess swelling after dermal fillers.

Novan Submits NDA for Berdazimer Gel for the Treatment of Molluscum Contagiosum

Potential FDA approval is expected in the first quarter of 2024.

Verrica Pharmaceuticals Announces Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions

VP-102 could be the first approved drug on the market in the US to treat molluscum contagiosum.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.